Skip to content
Invicta Diagnostic logo

Invicta Diagnostic

INVICTA NSE
₹68.00 +1.00 (+1.49%)
View as Markdown
MCP
Close 4 Nov 2026 ₹68.00 −28.70 −29.7% since 8 Dec 2025
Start ₹96.70

Key Fundamentals

SMEHealthcare ServicesHealthcare

Price-based figures as of · TTM

ROCE
19.40%
Debt to Equity
0.07
EPS (TTM)
—
Book Value
₹39.71
Market Cap
—
P/E (TTM)
—
P/B
1.71
ROE
14.00%
Dividend Yield
0.00%
EBITDA
₹10.50 Cr
52W High
₹105.00
52W Low
₹58.10
Day Range
₹67.00 – ₹68.00
Volume
4,800

Peer Comparison

Healthcare › Healthcare Services › Healthcare Service Provider

Invicta Diagnostic peer comparison
Dr Lal Pathlabs
₹2,029.4062.75₹32,036 Cr13.580.26%22.30%28.00%₹2,891 Cr₹545 Cr
Vijaya Diagnostic Centre
₹1,424.6078.15₹14,588 Cr15.330.14%18.30%20.50%₹857 Cr₹187 Cr
Metropolis Healthcare
₹581.2559.74₹11,437 Cr8.030.88%13.60%17.80%₹1,710 Cr₹203 Cr
Thyrocare Technologies
₹495.5044.72₹7,723 Cr14.252.90%28.40%35.40%₹876 Cr₹176 Cr
Nephrocare Health Services
₹622.35148.53₹5,903 Cr5.610.00%8.83%15.30%₹1,053 Cr₹85 Cr
Suraksha Diagnostic
₹333.0548.41₹1,717 Cr7.080.15%14.20%17.30%₹325 Cr₹35 Cr
Krsnaa Diagnostics
₹483.0515.84₹1,571 Cr1.510.41%10.90%12.70%₹726 Cr₹98 Cr
Invicta Diagnostic (this company)
₹68.00—₹84 Cr1.710.00%14.00%19.40%——
Median 8 companies₹538.3859.74₹6,813 Cr7.560.21%14.10%18.60%₹876 Cr₹176 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

43 Weak

Data confidence 81/100

Category scores

Quality
55
Good
Returns, margins, earnings quality 22% weight
Valuation
36
Poor
Cheap vs sector & own history 24% weight
Growth
47
Average
Sales & profit trajectory 9% weight
Financial Health
76
Strong
Solvency, leverage, coverage 9% weight
Momentum
35
Poor
Trend strength, vol-adjusted 12% weight
Ownership
33
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

1
  • Though the company is reporting repeated profits, it is not paying out dividend

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish658
OscillatorsNeutral252
Moving AveragesStrong Bullish406

Key readings

RSI (14)
54.15
Neutral
MACD (12,26,9)
−0.42
Bullish
SMA (50)
68.04
Bearish
SMA (200)
71.05
Bearish

As of

Growth Rate

From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
3Y+63.07%
1Y+7.48%

Net profit

Net profit growth by window
3Y+40.49%
1Y−1.01%

Operating cash flow

Operating cash flow growth by window
3Y—
1Y−55.34%

3Y: The statements do not go back far enough for this window.

Operating margin· change in pp

Operating margin growth by window
3Y−13.23 pp
1Y−0.33 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2023₹7.46 Cr
Mar 2024₹7.99 Cr
Mar 2025₹30.10 Cr
Mar 2026₹32.35 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2023₹1.76 Cr
Mar 2024₹2.69 Cr
Mar 2025₹4.93 Cr
Mar 2026₹4.88 Cr

Half-yearly Results

₹ Cr
INVICTA half-yearly results, ₹ crore
Particulars Sep 2025Mar 2026
Sales
16.95
15.41
Expenses
10.19
12.42
Operating Profit
6.76
2.99
OPM %
39.88%
19.4%
Other Income
0.13
0.56
Interest
0.1
0.09
Depreciation
1.37
1.88
PBT
5.42
1.58
Tax %
24.72%
50%
Net Profit
4.08
0.79
EPS (₹)
4.32
0.72

Profit & Loss

₹ Cr
INVICTA profit and loss, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Sales
7.46
7.99
30.1
32.35
Expenses
4.22
4.59
20.91
22.58
Operating Profit
3.24
3.4
9.19
9.77
OPM %
43.43%
42.55%
30.53%
30.2%
Other Income
0
0.35
0.09
0.69
Interest
0.02
0.08
0.23
0.2
Depreciation
0.95
0.98
2.49
3.25
PBT
2.27
2.69
6.56
7.01
Tax %
22.91%
0%
25%
30.39%
Net Profit
1.76
2.69
4.93
4.88
EPS (₹)
—
3.2
5.81
3.91
Div. Payout %
0%
0%
0%
0%

Balance Sheet

₹ Cr
INVICTA balance sheet, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
—
0.13
8.42
12.57
Reserves
—
12.05
5.18
37.35
Borrowings
—
1.87
3.53
3.67
Other Liabilities
—
1.79
4.09
6.65
Total Liabilities
—
15.84
21.22
60.24
Fixed Assets
—
11.78
9.58
19.2
CWIP
—
0
0
0
Investments
—
0
4.33
6.2
Other Assets
—
4.06
7.31
34.84
Total Assets
—
15.84
21.22
60.24

Cash Flow

₹ Cr
INVICTA cash flow, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Operating
—
4.21
6.56
2.93
Investing
—
−10.01
−5.23
−13.67
Financing
—
7.14
−0.5
30.79
Net Cash Flow
—
1.34
0.83
20.05
Free Cash Flow
—
−8.56
6.23
−9.93
CFO/EBITDA
—
124
71
40

Ratios

INVICTA financial ratios, annual
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
37.46
17.7
6.43
Inventory Days
—
297
83.33
78.88
Days Payable
—
1,103
70
254
Cash Conversion Cycle
—
−769
31.04
−169
Working Capital Days
—
5.94
18.55
55.74
ROCE %
—
—
45.04%
19.43%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Invicta Diagnostic insights

57 extracted metrics across FY23–FY26.

Shareholding Pattern

As of Sep 2026

  • Promoters 66.70%
  • Public 21.14%
  • Others 6.38%
  • DIIs 4.25%
  • FIIs 1.54%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Invicta Diagnostic

What does Invicta Diagnostic Ltd do?
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions
Where is Invicta Diagnostic Ltd (INVICTA) listed?
Invicta Diagnostic Ltd trades as INVICTA on the NSE.
Which sector does Invicta Diagnostic Ltd belong to?
Invicta Diagnostic Ltd is classified under the Healthcare Services sector, in the Healthcare Service Provider industry.
What is the 52-week high and low of Invicta Diagnostic Ltd?
Over the last 52 weeks Invicta Diagnostic Ltd has traded between ₹58.1 and ₹105 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Invicta Diagnostic Ltd?
Invicta Diagnostic Ltd reported a return on equity of 14.00%. Its debt-to-equity ratio is 0.07.

Company Information

Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions

Website pcdiagnostics.in
Listed 8 Dec 2025
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/INVICTA.md for Invicta Diagnostic Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month